New progress in roles of nitric oxide during hepatic ischemia reperfusion injury

Ya-Qi Zhang, Ning Ding, Yong-Fen Zeng, Yuan-Yuan Xiang, Mei-Wen Yang, Fen-Fang Hong, Shu-Long Yang

Ya-Qi Zhang, Ning Ding, Yong-Fen Zeng, Yuan-Yuan Xiang, Mei-Wen Yang, Shu-Long Yang, Department of Physiology, Basic Medical College, Nanchang University, Nanchang 330006, Jiangxi Province, China

Fen-Fang Hong, Medical Experimental Teaching Center, Jiangxi Medical College, Nanchang University, Nanchang 330031, Jiangxi Province, China

Author contributions: Zhang YQ, Ding N, Zeng YF and Xiang YY contributed equally to this work, and they wrote the paper; Yang MW contributed to data collection and paper revision; Hong FF and Yang SL also contributed equally to this work, they are responsible for the idea, fund and the paper revision.

Supported by National Natural Science Foundation of China, No. 81260504, No. 81660151 and No. 81660751; Science Foundation of Science Commission of Jiangxi Province, China, No. 20161BBG70067; School Teaching Reform Fund of Nanchang University, No. NCUIGLX - 14-1-111.

Conflict-of-interest statement: There is no conflict of interest associated with any of the authors in this manuscript.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Correspondence to: Shu-Long Yang, PhD, Professor, Department of Physiology, Basic Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, Jiangxi Province, China. slyang@ncu.edu.cn
Telephone: +86-791-86360556
Fax: +86-791-86360556

Received: December 6, 2016

Peer-review started: December 8, 2016
First decision: December 30, 2016
Revised: January 11, 2017
Accepted: February 16, 2017
Article in press: February 16, 2017
Published online: April 14, 2017

Abstract

Hepatic ischemia reperfusion injury (HIRI) is a clinical condition which may lead to cellular injury and organ dysfunction. The role of nitric oxide (NO) in HIRI is complicated and inconclusive. NO produced by endothelial nitric oxide synthase (eNOS) activation plays a protective role during early HIRI. But eNOS overexpression and the resulting excessive NO bioavailability can aggravate liver injury. NO induced by inducible nitric oxide synthase (iNOS) may have either a protective or a deleterious effect during the early phase of HIRI, but it may protect the liver during late HIRI. Here, we reviewed the latest findings on the role of NO during HIRI: (1) NO exerts a protective effect against HIRI by increasing NO bioavailability, downregulating p53 gene expression, decreasing inflammatory chemokines, reducing ROS via inhibiting the mitochondrial respiratory chain, activating sGC-GTP-cGMP signal pathway to reduce liver cell apoptosis, and regulating hepatic immune functions; (2) eNOS protects against HIRI by increasing NO levels, several eNOS/NO signal pathways (such as Akt-eNOS/NO, AMPK-eNOS/NO and HIF-1α-eNOS/NO) participating in the anti-HIRI process, and inhibiting over-expression of eNOS also protects against HIRI; and (3) the inhibition of iNOS prevents HIRI. Thus, the adverse effects of NO should be avoided, but its positive effect in the clinical treatment of diseases associated with HIRI should be recognized.

Key words: Liver; Hepatic ischemia reperfusion injury; Nitric oxide; Nitric oxide synthase
INTRODUCTION

Hepatic ischemia reperfusion injury (HIRI) is a clinical condition which may lead to cellular injury and organ dysfunction, mediated mainly through the production of reactive oxygen species and inflammatory cytokines[1]. Deterioration of hepatic homeostasis, as observed in IR, cold preservation and transplantation, septic organ failure, and hepatic resection-induced hyperperfusion, are associated with high rates of morbidity and mortality. It is well known that HIRI involves several mechanisms, which include pH imbalance, Ca\(^{2+}\) overload, mitochondrial damage induced by oxygen free radicals, endothelin (ET)/nitric oxide (NO) ratio imbalance, liver microcirculation dysfunction, activation of Kupffer cells and neutrophils, and the impact of various cytokines. During IR, there are interactions among liver cells, Kupffer cells, neutrophils, hepatic sinusoidal endothelial cells, and fat-storing cells. Platelets and alexin are also involved[2]. These activated cells release a large quantity of proinflammatory cytokine and lipid inflammatory factor, which can lead to inflammatory reaction and cell apoptosis.

NO is an unstable carbon-centered radical with a half-life of about 10 seconds. There are two sources in organisms: one is non-enzymigenes derived from the degradation or transformation of inorganic nitrogen chemicals in the body and food; and the other one is enzymigenes, in which NO is produced in a reductive reaction between L-arginine and oxygen molecules by NO synthase (NOS) catalysis. There are three types of NOS: endothelial nitric oxide synthase (eNOS), neuronal nitric oxide synthase (nNOS), and inducible nitric oxide synthase (iNOS). Endothelial nitric oxide synthase exists mainly in vascular endothelial cells while iNOS exists mainly in the cytoplasm of some inflammatory cells, such as white blood cells associated with diseases characterized by inflammation, tumors, and degeneration. NOS not only appears in soluble cytoplasm but also in some subcellular organelles. NO is produced mainly by eNOS catalysis, and also by upregulation of iNOS expressions during acute hepatic ischemia[3]. It has been reported that iNOS is induced to produce large amounts of NO by lipopolysaccharide, interleukin-1 (IL-1), and tumor necrosis factor (TNF), which play a role in the pathobiological process of some diseases and in many inflammation and immune reactions[4]. iNOS-derived NO may have either a protective or a deleterious effect during the early phase of IR injury, but it plays a protective role in the late phase of HIRI[5] (Table 1).

PROTECTIVE EFFECT OF NO DURING HIRI

NO was proved to reduce HIRI through various mechanisms[6,7], such as inhibiting liver cell apoptosis, slowing the infiltration of macrophages, eliminating superoxide anion produced by neutrophils, protecting the liver sinus structure and maintaining liver microcirculation blood flow, accelerating the liver tissue oxygenation, stabilizing ATP levels, decreasing oxidative stress injury, preventing the reduction of glutathione and the increase of endothelin side effects, and inhibiting platelet aggregation.

Increase of NO bioavailability involved in its protective effect in HIRI

In addition to NO donors, an increase in NO bioavailability can also protect the liver from HIRI. Human serum albumin (HSA) is a non-glycosylated protein, by which a series of recombinants, and mannosylated-HSA mutants (Man-rHSA) are prepared; their triple mutant (TM-rHSA) can be selectively delivered to the liver via a mannose receptor on non-parenchymal liver cells, which can effectively deliver NO to the liver and have a significant inhibitory effect against HIRI[8].

NO downregulates the expression of the p53 gene and decreases inflammatory chemokines

During IR, NO donors may decrease p53 gene expression and the levels of IL-1 and TNF-α as well as inhibit cell apoptosis to protect the heart, liver, lungs, and kidneys from IR injury. Elevated NO levels can inhibit p53 gene expression and decrease the production of proinflammatory cytokines and chemokines, such as intercellular adhesion molecule (ICAM), TNF-α, IL-1, MIP-1, and MIP-2. In particular, lower levels of ICAM,
Using transgenic knockout rats, Datta studied the molecular mechanism of HIRI. It was found that the initial liver injury is initiated by reactive oxygen species, which cause direct cellular injury and also activate a cascade of molecular mediators, leading to microvascular changes, increased apoptosis, and acute inflammatory changes with increased hepatocyte necrosis. However, during the period of reperfusion, some adaptive changes occur in order to reduce hepatocyte necrosis. Hence, NO reduces ROS production by inhibiting the mitochondrial respiratory chain.

**NO reduces ROS by inhibiting the mitochondrial respiratory chain**

Using transgenic knockout rats, Datta studied the molecular mechanism of HIRI. It was found that the initial liver injury is initiated by reactive oxygen species, which cause direct cellular injury and also activate a cascade of molecular mediators, leading to microvascular changes, increased apoptosis, and acute inflammatory changes with increased hepatocyte necrosis. However, during the period of reperfusion, some adaptive changes occur in order to reduce hepatocyte necrosis. Hence, NO reduces ROS production by inhibiting the mitochondrial respiratory chain.

**Table 1: Roles of nitric oxide, endothelial nitric oxide synthase and inducible nitric oxide synthase in pharmacological protection against hepatic ischemia reperfusion injury**

| Pretreatment            | NO/INOS/eNOS levels | Animals | Experimental cells | Mechanism                                                                 | Liver cell necrosis and liver damage | Ref. |
|-------------------------|----------------------|---------|--------------------|---------------------------------------------------------------------------|--------------------------------------|------|
| L-arginine and HIRI     | NO↑                  | Male Sprague-Dawley rats | Hepatocytes          | O2−, NO2-/NO3- concentration↑                                               | ↓                                   | [6]  |
| L-NAME and HIRI         | NO↓                  | Male Sprague-Dawley rats | Liver cells          | NO2-/NO3- concentration↓                                                   | ↑                                   | [7]  |
| Human serum albumin     | NO↑                  | Rats underwent HIRI       | Liver parenchyma      | Man-rHSAs↑                                                                | ↓                                   | [8]  |
| SNAP and HIRI           | NO↑                  | -                    | Vein endothelial cells | ICAM, TNF-α, NF-κB, p38, ERK, JNK, p55, caspase-3↑                           | ↓                                   | [9,10] |
| Nitrile and hypoxia/reoxygenation | NO↑      | Trachemys scripta elegans | Various cell types   | Cytochrome oxidase, oxygen radical↓                                      | ↓                                   | [13] |
| L-arginine and HIRI     | NO↑                  | -                    | Liver cells          | sGC, cGMP, PKG, PI3K, V-ATPase, ↑, intracellular Na+, H+↑                   | ↓                                   | [5]  |
| L-arginine and HIRI     | NO↑                  | -                    | Liver cells          | TNF-α, IL-1β↑                                                            | ↓                                   | [14,15] |
| HIRI                    | eNOS, NO↑            | -                    | Bovine aortic endothelial cells and COS-7 cells | Intracellular Na+, H+, PKC, Ca2+↑                                        | ↓                                   | [16,17] |
| rHuEPO and HIRI         | NO↑                  | Adult male Sprague-Dawley rats | Liver cells | PI3K/Akt/eNOS pathway                                                      | ↓                                   | [18] |
| Institut Georges Lopez-I and HIRI | eNOS↑      | Adult male SD rats | Liver cells          | Akt, AMPK↑                                                               | ↓                                   | [19] |
| Adiponectin and HIRI    | eNOS↑                | Adult male Wistar rats  | Hepatocytes          | AMPK/eNOS pathway                                                        | ↓                                   | [20] |
| Heparin cofactor II and ischemia | eNOS↑        | Male heterozygote HC-2 deficient mice and male littermate | Vascular endothelial cell | AMPK/eNOS signaling pathway                                                | ↓                                   | [21] |
| Trimetazidine, IGL-1, and HIRI | eNOS, NO↑ | Isolated perfused rats liver model | WT mice              | HIF-1α, heme-oxygenase-1↑                                               | ↓                                   | [22] |
| Knockdown of AK13928 and HIRI | eNOS↑       | Mice                  | Steatotic and non-steatotic livers cells | p-eNOS, p-Akt, PGSK-3 ↑, macrophage infiltration, NF-xB↓                  | ↓                                   | [23] |
| Ad-eNOS and HIRI        | eNOS↑                | Male inbred C57BL/6 lean mice | Liver cells | ATP↓, bax↑                                                                   | ↑                                   | [24] |
| Riboflavin and HIRI     | eNOS, INOS, NO↑      | Mice                  | Liver cells          | GSH↑                                                                    | ↑                                   | [25] |
| Rosmarinic acid and HIRI| eNOS, INOS, NO↑     | Rats                  | Liver cells          | eNOS excessive expression↑, NF-κB activity, TNF-α and IL-1β gene expression↑ | ↓                                   | [26] |
| Alpha lipoic acid and HIRI | INOS, NO↑       | Male Wistar strain rats | Hepatocytes          | iNOS mRNA stability↓                                                      | ↓                                   | [31] |

<: No data; Man-rHSAs: Mannosylated-HSA mutants; HIRI: Hepatic ischemia reperfusion injury; IGL-1: Institut georges lopez-1; SNAP: S-nitroso-N-acetylpenicillamine; ICAM: Intercellular adhesion molecule; Akt: Protein kinase B; AMPK: Adenosine monophosphate-activated protein kinase; TNF-α: Tumor necrosis factor-α; NF-κB: Nuclear factor-κB gene binding; ERK: Extracellular regulated protein kinase; JNK: c-Jun N-terminal kinase; PI3K: Phosphoinositide 3-kinase; V-ATPase: Vacuolar H⁺-ATPase; rHuEPO: Recombinant human erythropoietin; HIF-1α: Hypoxia inducible factor 1α; PGSK-3: Phosphorylated glycogen synthase kinase 3; eNOS: Endothelial nitric oxide synthase; iNOS: Inducible nitric oxide synthase.

MIP-1, and MIP-2 are accompanied by less neutrophil infiltration[9,10]. The application of ICAM-1 monoclonal antibody 1A29F is likely to provide a more effective treatment for primary grafted liver dysfunction[11]. NO can also reduce the level of TNF-α to inhibit NF-κB. Decreased NF-κB can inhibit MAPKs, including p38, ERK, and JNK. A reduced p38 level can lead to the inhibition of caspase-3 and gene p53 expression. Thus, the downregulation of p53, ERK and JNK results in reduction of cell inflammation[9].

**NO reduces ROS by inhibiting the mitochondrial respiratory chain**

Using transgenic knockout rats, Datta studied the molecular mechanism of HIRI. It was found that the initial liver injury is initiated by reactive oxygen species, which cause direct cellular injury and also activate a cascade of molecular mediators, leading to microvascular changes, increased apoptosis, and acute inflammatory changes with increased hepatocyte necrosis. However, during the period of reperfusion, some adaptive changes occur in order to reduce HIRI[11]. Exogenously administered NO donors can inhibit the oxidation of mitochondrial cytochrome and reduce ROS production. Excessive ROS is generated in liver cells after its hypoxia/reoxygenation, which causes protein oxidation and lipid peroxidation. Hence, NO reduces ROS production by inhibiting
mitochondrial respiratory chain complexes\[^{[13]}\].

**NO activates sGC-GTP-cGMP signaling pathway to reduce liver cell apoptosis**

NO derived from blood vessels can activate soluble guanylyl cyclase (sGC), catalyzing guanosine triphosphate (GTP) to produce cyclic 3', 5' guanosine monophosphate (cGMP). The protection of cGMP-dependent protein kinase (PKG) activated by cGMP results in the activation of PI3K and the phosphorylation of p38 MAPK, leading to the activation of vacuolar H^+\text{-ATPases} (V-ATPases), which lead to the extrusion of [H^+] ([H^+]\text{)} from the cytosol of hepatocytes into the extracellular environment, thereby resulting in inhibition of the H^+\text{-driven Na^+}/H^+ exchanger (NHE) and Na^+/HCO\text{-cotransporter} (NHCT), with a consequent reduction in [Na^+] ([Na^+]\text{)} and protection from hepatocyte death\[^{[5]}\]. Diao et al\[^{[11]}\] observed that NO plays an important protective role in organ preservation by supplementing sufficient NO donors to enhance the NO/cGMP pathway.

**NO regulates hepatic immune function**

NO is also an important effector molecule that is involved in immune regulation and host innate and acquired immunity. NO inhibits proinflammatory cytokines, including TNF-\alpha, IL-1\text{\textbeta}, IL-1\alpha, and IL-12, which may induce the inflammatory cascade during HIRI. In addition, NO can decrease the number of T helper 1 (Th1) cells and promote the proliferation of Th2 cells, regulate leukocyte adhesion, and induce the generation of T regulatory (Treg) cells\[^{[14,15]}\]. It has also been reported that excessive NO may paradoxically damage liver tissue by forming nitrogen peroxide, indicating that the dose of exogenous NO donors is vital to HIRI therapy.

**ENOS CONTRIBUTES TO PROTECTIVE FUNCTIONS AGAINST HIRI**

**ENOS activation increases NO levels**

Intracellular Ca\textsuperscript{2+} levels are the key factors that activate eNOS. During HIRI, Na\textsuperscript{+}/Ca\textsuperscript{2+} exchange protein on the cell membrane is activated directly or indirectly by the high concentration of Na\textsuperscript{+}, H\textsuperscript{+}, and PKC, leading to an increase in intracellular Ca\textsuperscript{2+}. Furthermore, with the liver cell membrane structure damaged, Ca\textsuperscript{2+} transports into the cellular membrane increased, and the endoplasmic reticulum and sarcoplasmic reticulum are also destroyed, which inhibits the function of the calcium pump to elevate the intracellular Ca\textsuperscript{2+} concentration. Meanwhile, stored intracellular Ca\textsuperscript{2+} is released. All these may lead to a higher intracellular Ca\textsuperscript{2+} concentration, which activates eNOS to produce more NO\[^{[16,17]}\]. The basic low-dose NO catalyzed by eNOS could mitigate the hepatic microcirculation pressure caused by reperfusion.

**ENOS/NO SIGNALING PATHWAYS PARTICIPATE IN ANTI-HIRI ACTIVITY**

**Akt-eNOS/NO pathway**

PI3K is a heterodimer composed of the catalytic subunit p10 and regulatory subunit p85, and is also a lipid second messenger. PI3K can phosphorylate the serine/threonine of its downstream signal kinase Akt, which may further phosphorylate eNOS to promote an increase in endogenous NO generation. The protective effect of rhHuEPO in IR injury is mediated via the activation of the PI3K/AKT/eNOS signaling pathway, at least in part, by increasing p-AKT and p-eNOS, which leads to the maintenance of an elevated level of NO\[^{[18]}\]. It has been reported that IGL-1 solution results in better liver preservation and protection against HIRI by activating Akt and AMPK, which are concomitant with increased eNOS expression and nitrite/nitrate levels\[^{[19]}\].

**AMPK-eNOS/NO pathway**

Zhang C reported that adiponectin (APN) can protect the liver from HIRI by reducing the inflammatory reaction and hepatocyte apoptosis, the process that likely involves the AMPK/eNOS pathway\[^{[20]}\]. In addition, heparin cofactors II (HCII) potentiates hepatic vascular endothelial cell activity and the promotion of angiogenesis via an AMPK/eNOS signaling pathway to decrease vascular injury\[^{[21]}\].

**HIF-1\alpha-eNOS/NO pathway**

Adding trimetazidine, an anti-ischemia drug, to IGL-1 induces NO and eNOS activation. In normoxic reperfusion, the presence of NO favors hypoxia-inducible factor-1\alpha (HIF-1\alpha) accumulation, and also promotes the activation of other cytoprotective genes to reduce HIRI, such as heme-oxygenase-1. In addition, NO could reduce HIRI via the HIF-1\alpha/NO pathway\[^{[22]}\].

**Other new pathways**

Deregulated long noncoding RNA (LncRNAs) AK139328 is involved in HIRI. In the IR liver, the knockdown of AK139328 increases survival-signaling proteins including phosphorylated Akt (pAkt), glycogen synthase kinase 3 (pGSK3), and endothelial nitric oxide synthase (peNOS). Furthermore, the knockdown of AK139328 also reduces macrophage infiltration and inhibits NF-\kappaB activity and inflammatory cytokine expression\[^{[23]}\]. This could provide some new options for the diagnosis and treatment of liver diseases, such as surgery or transplantation.

**Inhibition of eNOS overexpression to protect HIRI**

The most current evidence supports the idea that the overexpression of eNOS is detrimental in the setting of hepatic IR\[^{[24]}\]. Sanches SC found that during HIRI, the riboflavin infusion partially recovered hepatic GSH reserves and decreased eNOS/iNOS and NO levels in
the liver, and that riboflavin could have antioxidant and anti-inflammatory effects in the ischemic liver, protecting hepatocytes against IR injury.\(^{[25]}\)

Rosmarinic acid, which is a kind of water-soluble phenolic acid compound and a natural antioxidant, has many biological functions, such as antibacterial, antiviral, and anti-inflammatory effects, prevention of high calcium concentrations in the cell, and regulation of immune function. Also, it could inhibit eNOS overexpression in the liver; decrease eNOS/INOS and NO levels in the liver; attenuate NF-xB activation, downregulate TNF-\(\alpha\) and IL-1\(\beta\) gene expression, and exert anti-inflammatory and antioxidant effects in the ischemic liver, thereby protecting hepatocytes against IRI.\(^{[26]}\)

**ROLE OF INOS IN HIRI**

During sudden hepatic ischemic stress, upregulated iNOS in the liver produces a large quantity of NO as a response. However, up-regulating the expressions of iNOS gene and protein requires time.\(^{[7]}\)

**iNOS aggravates HIRI**

Some evidence suggests that eNOS can lead to “dysfunction” during oxidative stress, so production of a large amount of NO against IRI appears to be necessary for the expression of iNOS.\(^{[27,28]}\) Hu et al.\(^{[29]}\) discovered that while the expression of iNOS mRNA peaked 3 h after hepatic reperfusion, the highest protein level appeared after 6 h. After 4 h of reperfusion, the increased iNOS mRNA transcription did not result in increased NO production, and this lack of increase may be linked to different degrees of tissue damage.\(^{[30]}\)

**Inhibition of iNOS prevented liver from HIRI**

Alpha lipoic acid (\(\alpha\)-LA) has been shown to alleviate HIRI in rats. The underlying mechanism may be that \(\alpha\)-LA inhibits the expression of the iNOS gene antisense-transcript, which is involved in iNOS mRNA stability. Therefore, there may be useful therapeutic effects associated with the suppression of iNOS induction involved in liver injury.\(^{[31]}\)

IL-1\(\beta\) and TNF-\(\alpha\) are important proinflammatory cytokines.\(^{[14]}\) The upregulation of IL-1\(\beta\) receptors accelerates the iNOS transcription process, but the mechanism involved in its downstream signaling pathway is unknown.\(^{[32]}\) Blocking IL-1 receptors may be a way to alleviate HIRI. Although it is uncertain whether the reduction of IL-1 receptors is related to iNOS transcription, it does show that iNOS is involved in the process.\(^{[33]}\)

**CONCLUSION**

NO plays a complicated role during HIRI. NO can inhibit the expression of p53 gene and the aggregation of proinflammatory cytokines and chemokines, reduce ROS by inhibiting the mitochondrial respiratory chain, participate in hepatic immune modulation, inhibit the inflammatory cascade, and exhibit anti-inflammatory properties. In addition, as the first messenger, NO activated the NO/cGMP pathway to inhibit [Na\(^{+}\)]\(_i\) from entering the cells, thereby helping to maintain hepatic cell integrity. Conversely, excessive NO in serum can aggravate liver injury. Elevating NO levels appropriately, such as by applying exogenous NO donors or increasing NO availability in the liver, may be a good way to prevent and treat HIRI. There are two ways to activate eNOS which can promote an increase in endogenous NO generation to protect liver tissue from HIRI. One is elevating Ca\(^{2+}\) levels in cells or phosphorylating the active site of eNOS gene, and the other is knocking out gene AK139328. Both can protect the liver from HIRI. But excessive NO levels derived from eNOS are detrimental to the liver. iNOS has a synergistic effect with some inflammatory mediators, which cause cellular swelling and apoptosis. Excessive NO derived from iNOS plays a protective role in the late period of HIRI. Thus, adverse effects of NO should be avoided, and its positive effects in the clinical treatment of diseases associated with HIRI should be recognized.

**REFERENCES**

1. Zaki HF, Abdelsalam RM. Vinpocetine protects liver against ischemia-reperfusion injury. Can J Physiol Pharmacol 2013; 91: 1064-1070 [PMID: 24289077 DOI: 10.1139/cjpp-2013-0009]
2. Zeng Z, Huang HF, Chen MQ, Song F, Zhang YJ. Heme oxygenase-1 protects donor livers from ischemia/reperfusion injury: the role of Kupffer cells. World J Gastroenterol 2010; 16: 1285-1292 [PMID: 20222175 DOI: 10.3748/wjg.v16.i10.1285]
3. Miyake T, Yokoyama Y, Kokuryo T, Mizutani T, Imamura A, Nagino M. Endothelial nitric oxide synthase plays a main role in producing nitric oxide in the superacute phase of hepatic ischemia prior to the upregulation of inducible nitric oxide synthase. J Surg Res 2013; 183: 742-751 [PMID: 23485075 DOI: 10.1016/j.jss.2013.01.048]
4. Jiang WW, Kong LB, Li GQ, Wang XH. Expression of iNOS in early injury in a rat model of small-for-size liver transplantation. Hepatobiliary Pancreat Dis Int 2009; 8: 146-151 [PMID: 19357027]
5. Abu-Amara M, Yang SY, Seifalian A, Davidson B, Fuller B. The nitric oxide pathway--evidence and mechanisms for protection against liver ischaemia reperfusion injury. Liver Int 2012; 32: 531-543 [PMID: 22316165 DOI: 10.1111/j.1478-3231.2012.02755.x]
6. Rödens J, Mitjavila MT, Carbonell T. Nitric oxide inhibits superoxide production by inflammatory polymorphonuclear leukocytes. Am J Physiol 1998; 274: C827-C830 [PMID: 9530115]
7. Pannen BH, Al-Adili F, Bauer M, Clemens MG, Geiger KK. Role of endothelins and nitric oxide in hepatic reperfusion injury in the rat. Hepatology 1998; 27: 755-764 [PMID: 9507040 DOI: 10.1002/hep.510270317]
8. Hirata K, Maruyama T, Watanabe H, Maeda H, Nakajou K, Iwao Y, Ishima Y, Katsumi H, Hashida M, Otagiri M. Genetically engineered mannosylated-human serum albumin as a versatile carrier for liver-selective therapeutics. J Control Release 2010; 145: 9-16 [PMID: 20304018 DOI: 10.1016/j.jconrel.2010.03.010]
9. Phillips L, Toledo AH, Lopez-Neblina F, Anaya-Prado R, Toledo-Pereyra LH. Nitric oxide mechanism of protection in ischemia and...
reperfusion injury. J Invest Surg 2009; 22: 46-55 [PMID: 19191157 DOI: 10.1080/08941930802709470]

10. Waldow T, Witt W, Weber E, Matschke K. Nitric oxide donor-induced persistent inhibition of cell adhesion protein expression and NFκB activation in endothelial cells. Nitric Oxide 2006; 15: 103-113 [PMID: 16504556 DOI: 10.1016/j.niox.2005.12.005]

11. Diao TJ, Chen X, Deng LH, ChenHX, Liang Y, Zhao XD, Wang QH, Yuan WS, Gao BC, Ye Y. Protective effect of nitric oxide on hepatopulmonary syndrome from ischemia-reperfusion injury. World J Gastroenterol 2012; 18: 3310-3316 [PMID: 22783057 DOI: 10.3748/wjg.v18.i23.3310]

12. Datta G, Fuller BJ, Davidson BR. Molecular mechanisms of liver ischemia reperfusion injury: insights from transgenic knockout models. World J Gastroenterol 2013; 19: 1683-1698 [PMID: 23555157 DOI: 10.3748/wjg.v19.i11.1683]

13. Jensen FB, Hansen MN, Montesanti G, Wang T. Nitric oxide metabolites during anoxia and reoxygenation in the anoxia-tolerant vertebrate Trachemys scripta. J Exp Biol 2014; 217: 423-431 [PMID: 24104329 DOI: 10.1242/jeb.093179]

14. Guan LY, Fu PY, Li PD, Li ZN, Liu HY, Xin MG, Li W. Mechanisms of hepatic ischemia-reperfusion injury and protective effects of nitric oxide. World J Gastrointest Surg 2014; 6: 122-128 [PMID: 25068009 DOI: 10.4240/wjgs.v6.i2.122]

15. Liu P, Xu B, Spokas E, Lai PS, Wong PY. Role of endogenous nitric oxide in TNF-alpha and IL-1beta generation in hepatic ischemia-reperfusion. Shock 2000; 13: 217-223 [PMID: 10718379]

16. Yu N, Kong XY. Influence of endothelial Nitric Oxide Synthase (eNOS) on ischemia reperfusion tissue microcirculation[J]. Chinese Journal of Microcirculation 2013; 3: 65-67

17. Michel JB, Feron O, Sacks D, Michel T. Reciprocal regulation of endothelial nitric-oxide synthase by Ca2+-calmodulin and caveolin. J Biol Chem 1997; 272: 15583-15586 [PMID: 9188442 DOI: 10.1074/jbc.272.25.15583]

18. Fu W, Liao X, Ruan J, Li X, Chen L, Wang B, Wang K, Zhou J. Reconstituant human erythropoietin preconditioning attenuates liver ischemia reperfusion injury through the phosphorydialsinolost-3 kinase/AKT/endothelial nitric oxide synthase pathway. J Surg Res 2013; 183: 876-884 [PMID: 23490139 DOI: 10.1016/j.surge.2013.01.044]

19. Tabka D, Bejaoui M, Javelaud J, Roselló-Catafau J, Achard JM, Abdennabi HB. Effects of Institut Georges Lopez-1 and Celsior preservation solutions on liver graft injury. World J Gastroenterol 2015; 21: 4159-4168 [PMID: 25892865 DOI: 10.3748/wjg.v21.i14.4159]

20. Zhang C, Liao Y, Li Q, Chen M, Zhao Q, Deng R, Wu C, Yang A, Guo Z, Wang D, He X. Reconstituent adiponectin ameliorates liver ischemia reperfusion injury via activating the AMPK/eNOS pathway. PLoS One 2013; 8: e66382 [PMID: 23762489 DOI: 10.1371/journal.pone.0066382]

21. Ikeda Y, Aiha K, Yoshida S, Iwase T, Tajima S, Iwasa-Ishizawa Y, Kihira Y, Iishizawa K, Tomita S, Tsuichiya K, Sata M, Akaike M, Kato S, Matsumoto T, Tanaki T. Heparan cofactor II, a serine protease inhibitor, promotes angiogenesis via activation of the AMP-activated protein kinase-endothelial nitric-oxide synthase signaling pathway. J Biol Chem 2012; 287: 34256-34263 [PMID: 22904320 DOI: 10.1074/jbc.M112.353532]

22. Zaouali MA, Ben Mosbah I, Boncompagni E, Ben Abdennabi H, Mitjavila MT, Bartrons R, Freitas I, Rimola A, Roselló-Catafau J. Hypoxia inducible factor-lalphalpha accumulation in steatotic liver preservation: role of nitric oxide. World J Gastroenterol 2010; 16: 3499-3509 [PMID: 20653058 DOI: 10.3748/wjg.v16.i28.3499]

23. Chen Z, Jia S, Li D, Cai J, Tu J, Geng B, Guan Y, Cui Q, Yang J. Silencing of long noncoding RNA AK139328 attenuates ischemia/ reperfusion injury in mouse livers. PLoS One 2013; 8: e80817 [PMID: 23412245 DOI: 10.1371/journal.pone.0080817]

24. Palanisamy AP, Cheng G, Sutter AG, Liu J, Lewin DN, Chao J, Chavin K. Adenovirus-mediated eNOS expression augments liver injury after ischemia/reperfusion in mice. PLoS One 2014; 9: e93304 [PMID: 24667691 DOI: 10.1371/journal.pone.0093304]

25. Sanches SC, Ramalho LN, Mendes-Braz M, Terra VA, Cecchin R, Augusto MJ, Ramalho FS. Riboflavin (vitamin B-2) reduces hepatocellular injury following liver ischaemia and reperfusion in mice. Food Chem Toxicol 2014; 67: 65-71 [PMID: 24560968 DOI: 10.1016/j.fct.2014.02.013]

26. Ramalho LN, Pasta AA, Terra VA, Augusto M, Sanches SC, Souza-Neto FP, Cecchinini R, Guilan F, Ramalho FS. Rosmarinic acid attenuates hepatic ischemia and reperfusion injury in rats. Food Chem Toxicol 2014; 74: 270-278 [PMID: 25455994 DOI: 10.1016/j.fct.2014.10.004]

27. Hur GM, Ryu YS, Yun HY, Jeon BH, Kim YM, Seok JH, Lee JH. Hepatic ischemia/reperfusion in rats induces iNOS gene transcription by activation of NF-kappaB. Biochem Biophys Res Commun 1999; 261: 917-922 [PMID: 10441525 DOI: 10.1006/bbrc.1999.1143]

28. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994; 298 (Pt 2): 249-258 [PMID: 7510950 DOI: 10.1042/bj2980249]

29. Hu M, Wang Z, Rao J, Cao Y, Jiang W, Zhang F, Li X, Wang X. Inhibition of inducible nitric oxide synthase worsens liver damage regardless of lipopolysaccharide treatment in small-for-size liver transplantation. Transpl Immunol 2010; 23: 6-11 [PMID: 20206261 DOI: 10.1016/j.trim.2010.02.001]

30. Björnsson B, Winbladh A, Bojmar L, Sundqvist T, Gulstrand P, Sandström P. Conventional, but not remote ischemic preconditioning, reduces iNOS transcription in liver ischemia/ reperfusion. World J Gastroenterol 2014; 20: 9506-9512 [PMID: 25071345 DOI: 10.3748/wjg.v20.i28.9506]

31. Yamada M, Kaibori M, Tanaka H, Habara K, Hijikawa T, Tanaka Y, Oishi M, Okumura T, Nishizawa M, Kwon AH. alpha-lipoic acid prevents the induction of iNOS gene expression through destabilization of its mRNA in proinflammatory cytokine-stimulated hepatocytes. Dig Dis Sci 2012; 57: 943-951 [PMID: 22212728 DOI: 10.1007/s10620-011-2142-4]

32. Marangoni A, Accardo S, Aldini R, Guardigli M, Cavrini F, Sambri V, Montagnani M, Roda A, Cevenini R. Production of reactive oxygen species and expression of inducible nitric oxide synthase in rat isolated Kupffer cells stimulated by Leptospirosis interagens and Borrelia burgdorferi. World J Gastroenterol 2006; 12: 3077-3081 [PMID: 16718791 DOI: 10.3748/wjg.v12.i9.3077]

33. Hierholzer C, Harbretch B, Menezes JM, Kane J, MacMicking J, Nathan CF, Peitzman AB, Billiar TR, Tewary DJ. Essential role of inducible nitric oxide in the initiation of the inflammatory response after hemorrhagic shock. J Exp Med 1998; 187: 917-928 [PMID: 9500794 DOI: 10.1084/jem.187.6.917]
